PublishedHealthcare & Life SciencesMedical Devices & EquipmentGlobal

Wearable Cardiac Monitoring Devices Market Report 2026-2035

Wearable Cardiac Monitoring Devices Market by Product Type (ECG/Heart Rate Patches, Smartwatches with ECG, Wearable Holter Monitors, Chest Straps & Others), by Application (Arrhythmia Detection, Heart Failure Management, Post-Surgical Monitoring, Fitness & Wellness Monitoring), by End User (Homecare/Direct-to-Consumer, Hospitals & Clinics, Ambulatory Cardiac Centers), by Distribution Channel (Direct-to-Consumer/Retail, Hospital Procurement, Online Channels), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035

Author: Sneha ReddyReviewed by: Sunil BhosaleFact CheckedPublished:
Report codeVMI-1-2-70645
PublishedNovember 2026
Pages300+
Tables / figures98 / 72
Historical2023–2025
Base year2025
Forecast2026–2035
FormatPDF

Wearable Cardiac Monitoring Devices Industry Perspective

The Global Wearable Cardiac Monitoring Devices market was valued at USD 2,187.4 Mn in 2025 and is projected to reach USD 7,597.9 Mn by 2035, growing at a CAGR of 13.26% during the forecast period 2026–2035, according to Vectomat Insights.

North America is the largest regional market with a 37.0% share in 2025, worth USD 809.3 Mn, while Asia Pacific is the fastest-growing region, led by South Korea's 15.5% country CAGR.

Market size 2025USD 2,187.4 Mn
Forecast 2035USD 7,597.9 Mn
CAGR 2026–203513.26%
Largest regionNorth America37% share · fastest: Asia Pacific

Wearable Cardiac Monitoring Devices Market: Overview

Wearable Cardiac Monitoring Devices Market encompasses body-worn devices that capture electrocardiogram or heart rate data during normal daily life, together with the analysis that turns those signals into a clinical report or an alert. The report scope covers four product types (ECG/heart rate patches, smartwatches with ECG, wearable Holter monitors, and chest straps and other form factors), four applications, three end users and three distribution channels. Implantable loop recorders and in-hospital bedside telemetry sit outside the scope.

The value chain runs across three tiers. Foundational providers build the recorders and biosensor patches, led by Bittium, VitalConnect and HeartBeam. Specialist developers run prescription monitoring platforms that combine the device, AI-assisted ECG analysis and an independent diagnostic testing facility, the model used by iRhythm, Philips, Boston Scientific and AliveCor. Application-layer specialists such as Apple, Samsung Electronics and Google (Fitbit) put cleared cardiac software on mass-market consumer hardware.

For procurement and investment teams, value is concentrating where a cleared algorithm meets a reimbursed service. This report sizes that shift across 4 segmentation dimensions and 35+ countries, with base-year detail for 2025 and a ten-year forecast horizon to 2035.

According to World Health Organization, Cardiovascular diseases (CVDs) fact sheet, 2025, An estimated 19.8 million people died from cardiovascular diseases in 2022, about 32% of all deaths worldwide.

Wearable cardiac monitoring devices market at a glance — USD 2,187.4 Mn, 13.26% CAGR | Vectomat Insights
The market reaches USD 7,597.9 Mn by 2035; North America leads and Asia Pacific grows fastest. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

Key Insights

  • The Global Wearable Cardiac Monitoring Devices market rises from USD 2,187.4 Mn in 2025 to USD 7,597.9 Mn by 2035, a 13.26% CAGR over 2026–2035.
  • ECG/Heart Rate Patches are the dominant product type at 42.0% of 2025 revenue (USD 918.7 Mn), anchored by prescription long-term continuous monitoring such as iRhythm's Zio.
  • Smartwatches with ECG are the fastest-growing product type at a 17.87% CAGR, climbing from USD 656.2 Mn to USD 3,397.4 Mn and overtaking patches before 2035.
  • Arrhythmia Detection is the leading application at 39.8% of 2025 revenue (USD 870.1 Mn), because atrial fibrillation screening and diagnosis is the reimbursed core use case.
  • Homecare/Direct-to-Consumer is the dominant end user with 48.0% (USD 1,050.0 Mn) and grows at 16.76% a year, as monitoring moves out of the cardiology clinic and into the home.
  • North America holds 37.0% of 2025 revenue (USD 809.3 Mn); the U.S. alone accounts for USD 631.3 Mn and is forecast to reach about USD 1,978.3 Mn by 2035.
  • Asia Pacific is the fastest-growing region, with South Korea compounding at 15.5% and Japan at 13.6% a year, ahead of the U.S. (12.1%) and Germany (11.7%).
  • Consolidation is redrawing the competitive map: iRhythm agreed in August 2026 to buy VitalConnect for about USD 287.5 Mn to extend from ambulatory ECG into inpatient and hospital-to-home monitoring.
  • Online Channels are the fastest-growing distribution route at 19.77% a year, and Fitness & Wellness Monitoring is the fastest application at 19.69%, signalling a shift toward consumer-led cardiac data.
Wearable cardiac monitoring devices market size — USD 2,187.4 Mn in 2025 to USD 7,597.9 Mn by 2035 | Vectomat Insights
The global wearable cardiac monitoring devices market grows from USD 2,187.4 Mn in 2025 to USD 7,597.9 Mn by 2035, a 13.26% CAGR. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

Wearable Cardiac Monitoring Devices Market: Report Scope

Report NameWearable Cardiac Monitoring Devices Market by Product Type (ECG/Heart Rate Patches, Smartwatches with ECG, Wearable Holter Monitors, Chest Straps & Others), by Application (Arrhythmia Detection, Heart Failure Management, Post-Surgical Monitoring, Fitness & Wellness Monitoring), by End User (Homecare/Direct-to-Consumer, Hospitals & Clinics, Ambulatory Cardiac Centers), by Distribution Channel (Direct-to-Consumer/Retail, Hospital Procurement, Online Channels), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
Market Size in 2025USD 2,187.4 Mn (2025)
Market Forecast in 2035USD 7,597.9 Mn (2035)
Growth Rate (CAGR)13.26%
Historical Data Period2023–2025
Base Year2025
Forecast Period2026–2035
Number of Pages300+
Tables & Figures98 tables & 72 figures
Report CodeVMI-1-2-70645
Report FormatPDF
Delivery FormatPDF via email delivery and online download portal
Published DateNovember 2026
Research MethodologyPrimary interviews + secondary research + verified market sizing (top-down and bottom-up triangulation)
Key Companies CoverediRhythm Technologies, Apple, Samsung Electronics, Philips, Boston Scientific, Garmin, AliveCor, Google (Fitbit), Withings, Bittium, Omron Healthcare, Huawei, VitalConnect, HeartBeam, Biotricity
Segments CoveredProduct Type, Application, End User, Distribution Channel
Regions CoveredNorth America, Europe, Asia Pacific, Latin America, The Middle East, Africa
Customization ScopeUp to 10% free customization: additional country splits, extra company profiles, or deeper sub-segment cuts (for example patch wear duration or single-lead versus multi-lead ECG) on request

Why This Wearable Cardiac Monitoring Devices Market Report Matters

Decision-makers comparing market intelligence reports on Wearable Cardiac Monitoring Devices will find the VMI report differentiated on the following dimensions.

DimensionVMI ReportIndustry Average
Report Pages300+~120 pages
Forecast Horizon10 years7 years
Segmentation Dims4 dims4-5 dimensions
Historical Data3 years4-5 years
Country Coverage35+ countries15-18 countries
Companies Profiled15 companies10-12 companies
DROC FrameworkFull (4 elem)Drivers only

For custom scope — additional segments, specific geographies, or extended forecast periods — contact sales@vectomatinsights.com

Why Is the Wearable Cardiac Monitoring Devices Market Growing?

Undiagnosed Atrial Fibrillation Burden — Atrial fibrillation hides in plain sight. The Global Burden of Disease study counts about 59.7 million prevalent cases of atrial fibrillation and flutter, and the CDC expects the U.S. figure alone to reach roughly 12.1 million by 2030. Many episodes are intermittent and silent, so a 24-hour resting test misses them, while a 14-day patch or a watch worn every night does not. That diagnostic gap is the commercial base for prescription patches, which hold 42.0% of 2025 revenue. It also explains why stroke-prevention franchises, from Boston Scientific's left atrial appendage closure to ablation, now invest in the monitoring front end. As longer wear times become standard, the pool of diagnosable patients keeps expanding through 2035.

Smartwatch ECG Goes Mainstream — The ECG has moved onto the wrist. Apple, Samsung, Google, Garmin and Huawei all sell watches with a cleared ECG or irregular-rhythm feature, and Garmin added South Korea to its ECG App rollout in February 2026 after MFDS approval. Counterpoint reports that global smartwatch shipments returned to growth in 2025, with Huawei passing Apple in share for the first time. Every new watch sold adds a potential cardiac screening device at no extra cost to the buyer. That's why Smartwatches with ECG compound at 17.87% a year, from USD 656.2 Mn in 2025 to USD 3,397.4 Mn by 2035.

Reimbursement for Short Home Monitoring — Payment rules finally fit how cardiac studies work. The CMS CY2026 Physician Fee Schedule, finalised in October 2025, created remote physiologic monitoring codes for 2 to 15 days of data and a 10-minute management code, so short post-discharge or symptom-driven studies can be billed. Before 2026, practices needed 16 days of readings in a month to claim device supply. The change favours patches and multi-parameter biosensors sent home after surgery or a heart failure admission. Philips' September 2025 entry into Optum's network as a preferred cardiac monitoring provider shows payers lining up suppliers for this volume.

AI Interpretation Clears More Conditions — Each new clearance widens what a single recording can report. AliveCor's KAI 12L went from 35 determinations in 2024 to 39 in January 2026, Boston Scientific cleared deep-learning arrhythmia detection for BodyGuardian in January 2026, and Samsung's watch now screens ECG data for left ventricular systolic dysfunction. Algorithms cut the technician time per study, which protects service margins when payment is flat. They also move wearables from rhythm checks toward structural heart disease. In this market, an AI clearance works as a new product launch without new hardware.

Adding VitalConnect extends our cardiac monitoring platform beyond ambulatory care into inpatient and hospital-to-home settings, widening the patients we can reach.

— Quentin Blackford, President and Chief Executive Officer, iRhythm Technologies · Press (paraphrased) · iRhythm press release on the agreement to acquire VitalConnect, Aug 2026 [source]

Hypertension is a silent killer, and notifications on the watch can prompt people who don't know they have it to confirm with a cuff and see a doctor.

— Dr. Sumbul Desai, Vice President of Health, Apple · Press (paraphrased) · Express & Star (PA Media) interview on Apple Watch Hypertension Notifications, Sep 2025 [source]

What's Limiting the Wearable Cardiac Monitoring Devices Market?

Software Failures and Recall Risk — The weak point isn't the sensor. In January 2025 the FDA classed a recall of Philips' cardiac telemetry and monitoring service application as Class I, its most serious category, after a software configuration issue meant some ECG events never reached clinicians for review; two deaths were reported. As more analysis runs in the cloud and in AI models, a single software fault can affect thousands of patients at once. Hospitals now ask for post-market surveillance data and validation evidence before signing. Suppliers that can document software quality will carry a pricing edge through the rest of the decade.

False Alerts and False Reassurance — Accuracy limits cut both ways. Consumer irregular-rhythm alerts can send healthy users to cardiologists, adding low-yield visits, while a watch that stays silent can reassure people who are actually at risk. In a February 2026 interview, University of Utah researcher Adam Bress warned that Apple Watch hypertension notifications have low sensitivity, so a missing alert is no all-clear. Clinicians respond by ordering a prescription patch to confirm, which caps how far consumer devices can replace clinical ones. Fitness & Wellness Monitoring still grows at 19.69%, but it stays at 16.0% of 2025 revenue.

Cybersecurity and Data Liability — Continuous monitoring means continuous data exposure. In June 2026 iRhythm disclosed a cyberattack through a third-party application in which patient data was stolen and a ransom demanded. Cardiac records are long, identifiable and linked to insurance claims, so breaches carry regulatory and legal costs; iRhythm also booked about USD 95 Mn of litigation settlements in the third quarter of 2026. Hospital buyers now add security reviews that slow procurement. iRhythm's breach is the reference case procurement teams cite.

A missing alert from the watch doesn't rule out hypertension, so patients can come away falsely reassured when the feature's sensitivity is low.

— Adam Bress, PharmD, MS, Health-services researcher, University of Utah Health · Interview (paraphrased) · HCPLive interview, 10 Feb 2026 [source]

Emerging Opportunities in the Wearable Cardiac Monitoring Devices Market

Heart Failure Remote Programmes — Heart failure is the next big clinical use. The application grows at 15.71% a year, from USD 568.7 Mn in 2025 to USD 2,446.6 Mn by 2035, because discharged patients need weeks of follow-up and readmissions are expensive. NHS England has extended virtual wards to heart failure patients, and King Abdullah Medical City in Makkah launched smart heart-failure monitoring technology in July 2026. Samsung's watch screen for left ventricular systolic dysfunction adds a consumer on-ramp. Suppliers with multi-parameter patches and nurse-review services are best placed to win these contracts over the next decade.

Inpatient and Hospital-at-Home Wearables — The ward is the new territory. iRhythm's August 2026 agreement to buy VitalConnect brings a biosensor that records 11 physiological parameters for up to 30 days into a platform built for outpatients. In South Africa, Netcare agreed with Corsano Health in November 2025 to roll out continuous wearable monitoring across general wards. Post-Surgical Monitoring already holds 18.2% of 2025 revenue and grows at 11.59% a year. If ward deployments scale, Hospital Procurement could reach USD 2,946.0 Mn by 2035.

Emerging-Market Point-of-Care ECG — Low-cost portable ECG fits health systems short of cardiologists. AliveCor launched Kardia 12L in India in September 2025, where the national digital health ID system passed 900 million accounts in 2026 and can carry results into patient records. Garmin has extended its ECG App to Saudi Arabia and the UAE. These markets are small today, with Latin America at 5.0%, the Middle East at 4.0% and Africa at 3.0% of 2025 revenue. AliveCor's India launch is the first scaled test of point-of-care 12-lead ECG outside rich markets.

What's Holding Back the Wearable Cardiac Monitoring Devices Market?

Platform Power Over Accessory Makers — Owning the watch means owning the rules. In January 2026 the Ninth Circuit affirmed judgment for Apple against AliveCor's antitrust claims over heart-rhythm analysis on Apple Watch, after AliveCor's underlying patents had already been invalidated. Third-party ECG accessory makers now compete with features that ship free on the platform. Smaller firms will increasingly need clinical channels or acquisitions to survive.

Unclear Wellness-Versus-Medical Line — The regulatory line is moving. In January 2026 the FDA updated its general wellness and clinical decision support guidance, easing oversight of non-invasive wearables that report wellness metrics. That speeds consumer launches, but it lets unvalidated cardiac metrics reach users without clinical review. Buyers struggle to compare cleared and uncleared claims, while Fitness & Wellness Monitoring grows at 19.69% a year.

Clearance of the first cable-free synthesized 12-lead ECG, won on appeal, validates a platform that lets patients record a clinical-grade ECG at home when symptoms strike.

— Robert Eno, Chief Executive Officer, HeartBeam · Press (paraphrased) · HeartBeam press release on FDA 510(k) clearance K250258, 10 Dec 2025 [source]
Wearable cardiac monitoring devices market DROC — AF burden and smartwatch ECG drive growth | Vectomat Insights
Undiagnosed atrial fibrillation and mainstream smartwatch ECG drive the market, while software recalls, false alerts and cyber risk hold it back. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

Where AI Fits Into the Wearable Cardiac Monitoring Devices Market

Boston Scientific's January 2026 clearance for a BodyGuardian monitoring system built on an ensemble of deep neural networks is typical of where this market's AI sits: in the reading room, not on the skin. iRhythm reads Zio recordings with its own deep-learning models, AliveCor's KAI 12L now reports 39 cleared determinations, and Samsung screens watch ECGs for left ventricular systolic dysfunction. The FDA's AI-enabled device list puts cardiology second only to radiology.

For buyers, AI changes the cost of a study more than the device. Automated first reads cut technician time and shorten report turnaround to 24 to 48 hours, which protects margins when payment is flat. The risk is software quality, as Philips' January 2025 Class I recall showed, so validation evidence and post-market monitoring now sit at the centre of tenders.

Wearable Cardiac Monitoring Devices Market: Segmentation

The Global Wearable Cardiac Monitoring Devices market is segmented by Product Type, Application, End User, Distribution Channel.

By Product Type

Prescription monitoring and consumer wearables now share the same diagnostic pathway, and the product mix shows the strain. ECG/Heart Rate Patches are the dominant product type at 42.0% of 2025 revenue (USD 918.7 Mn), since each long-term continuous study is billed as a full diagnostic service. Smartwatches with ECG hold 30.0% (USD 656.2 Mn) but are the fastest-growing product, compounding at 17.87% a year to USD 3,397.4 Mn by 2035 and passing patches around 2030. Wearable Holter Monitors add 18.0% and grow at 13.89%, helped by recorders that now cover up to 30 days. Chest Straps & Others, at 10.0%, dipped in 2024 and grow only 5.94% a year. Apple's September 2025 FDA clearance for Hypertension Notifications shows how quickly the wrist adds cardiac indications.

Year-on-Year Wearable Cardiac Monitoring Devices Market Revenue By Product Type (2023–2025, USD Million)

Sub-Segment2023 (USD Mn)2024 (USD Mn)2025 (USD Mn)
ECG/Heart Rate Patches787.8863.2918.7
Smartwatches with ECG478.2577.4656.2
Wearable Holter Monitors264.1332.0393.7
Chest Straps & Others204.6199.8218.7
Wearable cardiac monitoring devices market share by product type — ECG patches 42.0% | Vectomat Insights
ECG/heart rate patches hold 42.0% of 2025 revenue, while smartwatches with ECG hold 30.0% and grow fastest at 17.87% a year. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

By Application

Atrial fibrillation remains the reason most studies are ordered. Arrhythmia Detection is the leading application at 39.8% of 2025 revenue (USD 870.1 Mn), though its growth flattened in 2025 and it compounds at just 7.81% a year through 2035. Fitness & Wellness Monitoring is the fastest-growing application at 19.69%, rising from USD 350.0 Mn to USD 2,111.3 Mn, because every new watch generation bundles richer heart features. Heart Failure Management follows at 26.0% and grows at 15.71%, the fastest clinical use, as remote programmes for discharged patients get paid as ongoing management. Post-Surgical Monitoring holds 18.2%. Samsung's October 2025 Galaxy Watch feature that screens ECG data for left ventricular systolic dysfunction marks the first move of consumer watches into heart-failure screening.

Year-on-Year Wearable Cardiac Monitoring Devices Market Revenue By Application (2023–2025, USD Million)

Sub-Segment2023 (USD Mn)2024 (USD Mn)2025 (USD Mn)
Arrhythmia Detection776.9863.1870.1
Heart Failure Management395.0454.3568.7
Post-Surgical Monitoring373.8407.1398.6
Fitness & Wellness Monitoring189.0247.9350.0

By End User

Medicare's 2026 remote-monitoring codes for 2 to 15 days of data changed where a cardiac study can happen. Homecare/Direct-to-Consumer is both the dominant and the fastest-growing end user, at 48.0% of 2025 revenue (USD 1,050.0 Mn) and a 16.76% CAGR that lifts it to USD 4,945.8 Mn by 2035. Hospitals & Clinics hold 32.0% (USD 700.0 Mn) and grow at 10.8%, still ordering most prescription patches and running inpatient wearable programmes. Ambulatory Cardiac Centers take 20.0%, slipped slightly in 2025, and grow at only 4.83%, since mail-order patches skip the clinic visit. HeartBeam's December 2025 clearance for a cable-free synthesized 12-lead home ECG shows the clinical tier following consumers into the home.

Year-on-Year Wearable Cardiac Monitoring Devices Market Revenue By End User (2023–2025, USD Million)

Sub-Segment2023 (USD Mn)2024 (USD Mn)2025 (USD Mn)
Homecare/Direct-to-Consumer725.3868.01,050.0
Hospitals & Clinics581.3658.2700.0
Ambulatory Cardiac Centers428.1446.2437.5
Wearable cardiac monitoring devices market share by end user — homecare 48.0% | Vectomat Insights
Homecare/direct-to-consumer buyers account for 48.0% of 2025 revenue and are also the fastest-growing end user at 16.76% a year. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

By Distribution Channel

Consumer electronics retail still moves the most value, but the growth is elsewhere. Direct-to-Consumer/Retail is the largest channel at 45.5% of 2025 revenue (USD 996.3 Mn), yet it grows at only 8.24% a year as watch pricing stays flat. Online Channels are the fastest-growing route at 19.77%, rising from USD 403.6 Mn to USD 2,452.0 Mn, as brand stores sell devices together with subscription review services. Hospital Procurement holds 36.0% and grows at 14.1%, overtaking retail before 2035 as patches, telemetry and inpatient biosensors are bought under multi-year service contracts. Withings' January 2025 launch of BPM Vision with a paid Cardio Check-Up cardiologist review is the online model in practice.

Year-on-Year Wearable Cardiac Monitoring Devices Market Revenue By Distribution Channel (2023–2025, USD Million)

Sub-Segment2023 (USD Mn)2024 (USD Mn)2025 (USD Mn)
Direct-to-Consumer/Retail896.5949.9996.3
Hospital Procurement562.0701.2787.5
Online Channels276.2321.3403.6
Wearable cardiac monitoring devices market segmentation — ECG patches lead product type at 42.0% | Vectomat Insights
ECG/heart rate patches, arrhythmia detection, homecare buyers and retail lead their dimensions in 2025. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

Wearable Cardiac Monitoring Devices Market: Production & Volume Analysis, 2025

This section counts units shipped: one patch or Holter recorder per study, one ECG watch or chest strap per sale. Vectomat Insights estimates 34.5 million units shipped in 2025, implying a blended average of about USD 63 of cardiac monitoring revenue per unit. Smartwatches with ECG account for 76.0% of units but 30.0% of revenue, because only the cardiac share of each watch's value, about USD 25, is counted. ECG/Heart Rate Patches take 12.0% of units yet 42.0% of revenue at roughly USD 220 per study, and Wearable Holter Monitors carry the highest value per unit at about USD 760.

Metric2025 Volume (units shipped)Share of Units
Total units shipped (2025)34,500,000100.0%
ECG/Heart Rate Patches4,140,00012.0%
Smartwatches with ECG26,220,00076.0%
Wearable Holter Monitors517,5001.5%
Chest Straps & Others3,622,50010.5%

Reference point: Bittium — Reported more than 600,000 Faros ambulatory ECG devices delivered to customers in more than 40 countries when it launched Faros Pro (August 2026). 600,000+ Faros devices in 40+ countries.

Wearable Cardiac Monitoring Devices Market: Competitive Landscape

Regulators decide who competes here, and both clinical and consumer firms are now collecting clearances at speed. iRhythm leads prescription monitoring with its Zio patches and guided FY2026 revenue to USD 870-880 Mn, and in August 2026 it agreed to buy VitalConnect to move into inpatient and hospital-to-home care. Philips and Boston Scientific compete with telemetry services and AI-read monitors, while AliveCor and HeartBeam push portable 12-lead ECG into the home. On the consumer side, Apple, Samsung and Huawei turn watches into screening tools, and Huawei passed Apple in global smartwatch share in 2025. Key players include iRhythm Technologies, Apple, Samsung Electronics, Philips, Boston Scientific, Garmin, AliveCor, Google (Fitbit), Withings, Bittium, Omron Healthcare, Huawei, VitalConnect, HeartBeam and Biotricity, among others.

CompanyHQ CountryPrimary FocusKey StrategyNotable Recent Action
iRhythm TechnologiesUnited StatesZio XT, Zio AT and Zio MCT ECG patches with deep-learning analysis and an independent diagnostic testing facilityOwn long-term continuous monitoring, then expand into MCT, primary care and hospital-to-homeAgreed in August 2026 to acquire VitalConnect for about USD 287.5 Mn and guided FY2026 revenue to USD 870-880 Mn in October 2026
AppleUnited StatesApple Watch ECG app, Irregular Rhythm Notifications, AFib History and Hypertension NotificationsShip FDA-cleared cardiac software on a mass consumer installed baseReceived FDA clearance for Apple Watch Hypertension Notifications in September 2025 and won the Ninth Circuit appeal against AliveCor in January 2026
Samsung ElectronicsSouth KoreaGalaxy Watch ECG and irregular heart rhythm notifications through Samsung Health MonitorAdd AI cardiac screening on the watch, launching first in KoreaIntroduced a Galaxy Watch ECG feature that screens for left ventricular systolic dysfunction in October 2025, starting in South Korea
PhilipsNetherlandsePatch extended Holter, mobile cardiac telemetry services and Cardiologs AI ECG analysisBundle patch hardware, AI analytics and monitoring services, sold through payer networksJoined Optum's network as a preferred provider of mobile cardiac telemetry in September 2025, after an FDA Class I recall of a telemetry service application in January 2025
Boston ScientificUnited StatesBodyGuardian MINI and MINI PLUS remote cardiac monitors (former Preventice) and the LUX-Dx insertable monitorUse diagnostics to feed its atrial fibrillation ablation and left atrial appendage closure franchisesReceived FDA clearance for the BodyGuardian Remote Monitoring System v3.0 with deep-learning arrhythmia detection in January 2026
GarminUnited StatesGarmin ECG App for AFib detection on Venu, fenix and epix watchesRoll out the ECG app country by country as each regulator approves itLaunched the ECG App in South Korea after MFDS approval in February 2026, following Japan in April 2025
AliveCorUnited StatesKardiaMobile 1-lead and 6-lead, Kardia 12L with KAI 12L AI and the KardiaCare serviceWiden AI determinations on portable ECG for clinicians and consumersWon FDA clearance for new KAI 12L determinations in January 2026, bringing the total to 39
Google (Fitbit)United StatesFitbit ECG app, irregular rhythm notifications and Pixel Watch Loss of Pulse DetectionAdd AI safety features to Pixel Watch and Fitbit devicesReceived FDA clearance for Loss of Pulse Detection on Pixel Watch 3 in February 2025
WithingsFranceScanWatch with ECG, BPM Vision and BPM Core blood pressure monitors, and the Cardio Check-Up servicePair cleared home devices with a paid cardiologist review subscriptionUnveiled BPM Vision and the Cardio Check-Up cardiologist review service at CES in January 2025
BittiumFinlandFaros 180, Faros 360 and Faros Pro ambulatory ECG recorders with Cardiac Navigator softwareSupply clinically validated long-term ECG hardware to hospitals and distributors outside the U.S.Launched the MDR-certified Faros Pro recorder and EasyFlex patch in August 2026, with more than 600,000 Faros devices delivered
Omron HealthcareJapanBlood pressure monitors with AFib detection and the Complete BP-plus-ECG deviceCombine blood pressure and AFib screening to cut stroke riskLaunched an atrial fibrillation clinical trial with UCSF in April 2026
HuaweiChinaWatch D2 with cuff blood pressure and ECG, and Watch GT series ECG and arrhythmia analysisRegister wearables as medical devices to stand apart from rivalsReported higher smartwatch sales from registering watches as medical devices in February 2025, and passed Apple in global smartwatch share in 2025
VitalConnectUnited StatesVitalPatch biosensor recording ECG, heart rate, respiration and temperature for up to 30 daysCover inpatient, outpatient and hospital-to-home monitoring with one patchAgreed in August 2026 to be acquired by iRhythm for about USD 287.5 Mn
HeartBeamUnited StatesCredit-card-sized, cable-free 3D-vector ECG with synthesized 12-lead outputBring 12-lead-equivalent arrhythmia assessment into the home, prescribed by physiciansReceived FDA 510(k) clearance for its synthesized 12-lead ECG software in December 2025 after an appeal
BiotricityUnited StatesBioflux mobile cardiac telemetry, Biotres patch and the Bioheart consumer monitorGrow recurring monitoring revenue with a capital-light device modelReported revenue growth and positive EBITDA for its third quarter of fiscal 2026 in February 2026

Strategic activity is converging on three themes. First, consolidation that adds acuity range, led by iRhythm's purchase of VitalConnect. Second, AI clearances as product differentiation: AliveCor's 39 KAI 12L determinations and Boston Scientific's deep-learning BodyGuardian release. Third, consumer platforms adding medical indications, from Apple's Hypertension Notifications to Samsung's heart-failure screen. Software risk sits underneath all three, shown by Philips' January 2025 Class I recall and iRhythm's June 2026 breach.

Wearable cardiac monitoring devices competitive positioning — iRhythm, Philips, Apple, Samsung lead | Vectomat Insights
iRhythm and Philips lead on clinical depth, while Apple and Samsung lead on scale and reach. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

Wearable Cardiac Monitoring Devices Market: From Raw Material to Delivery

Sensors, Electrodes & Recorder Hardware — Device makers source ECG front-end chips, flexible circuits, batteries and medical-grade adhesives, then assemble patches, recorders and watch sensors. Single-use adhesive patches are the volume consumable of the clinical tier, and wear time now stretches to 14 or 30 days. Bittium has delivered more than 600,000 Faros recorders, and VitalConnect's VitalPatch adds respiration and temperature sensing. Hardware margins are thin unless the device is tied to a billed service. Key Players: Bittium, VitalConnect, HeartBeam.

Analysis Platforms & Monitoring Services — Recorded ECG data is uploaded and read by deep-learning algorithms, then checked by certified technicians at an independent diagnostic testing facility before a physician gets the report. This is where most clinical revenue is earned, because the payer reimburses the study, not the hardware. iRhythm, Philips and Boston Scientific run their own reading centres, and AliveCor licenses AI interpretation. Software failures here carry clinical risk. Key Players: iRhythm Technologies, Philips, Boston Scientific, AliveCor, Biotricity.

Clinical & Consumer Delivery — Devices reach patients two ways. Prescription patches and telemetry are ordered by cardiologists and hospitals, often mailed straight to the patient's home. Consumer watches and handheld ECGs are sold through retail stores and online channels, and the cleared ECG app comes with the purchase. Payer networks such as Optum and hospital contracts shape the clinical path, while upgrade cycles drive the consumer one. Key Players: Apple, Samsung Electronics, Google (Fitbit), Garmin, Huawei, Withings, Omron Healthcare.

Wearable Cardiac Monitoring Devices Market: Regional Analysis

North America leads the Global Wearable Cardiac Monitoring Devices market with a 37.0% share in 2025, because Medicare pays for long-term ECG studies and remote monitoring. Asia Pacific is the fastest-growing region, with South Korea compounding at 15.5% a year as Samsung and Garmin win MFDS clearances for watch-based cardiac features.

North America Wearable Cardiac Monitoring Devices Market

Reimbursement sets the pace in North America, and 2026 brought a looser rulebook: Medicare now pays for remote monitoring periods as short as two days. The region holds 37.0% of the 2025 market (USD 809.3 Mn), and the United States contributes USD 631.3 Mn, forecast to grow at a 12.1% CAGR to about USD 1,978.3 Mn by 2035. iRhythm's Zio service anchors prescription demand, while Apple's Hypertension Notifications clearance in September 2025 widened the consumer funnel. The brake is payment volatility on long-term ECG codes, plus cyber risk after iRhythm's June 2026 data breach. With iRhythm folding VitalConnect into its platform, the U.S. is set to lead the move from ambulatory patches into hospital-to-home monitoring.

United States Wearable Cardiac Monitoring Devices Market Snapshot

MetricValue
Market Size (2025)USD 631.3 Mn
Forecast Value (2035)USD 1,978.3 Mn
CAGR (2026–2035)12.1%
United States wearable cardiac monitoring devices market — USD 631.3 Mn in 2025, 12.1% CAGR | Vectomat Insights
The United States market grows from USD 631.3 Mn in 2025 to about USD 1,978.3 Mn by 2035 at a 12.1% CAGR. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

Europe Wearable Cardiac Monitoring Devices Market

Europe buys cardiac monitoring through public health systems, so tenders and data rules matter more than consumer hype. The region accounts for 27.0% of 2025 revenue (USD 590.6 Mn). Germany leads with USD 171.3 Mn and grows at an 11.7% CAGR to about USD 518.0 Mn by 2035, supported by a reimbursed digital health route that was reworked in February 2026. In the U.K., NHS heart patients are monitored with Philips' ePatch and Cardiologs AI analysis, and Finland's Bittium launched its MDR-certified Faros Pro recorder at ESC Congress 2026. The principal challenge is MDR recertification, which strains smaller suppliers. Europe's demand stays rooted in Holter-grade clinical recording, which is why Wearable Holter Monitors hold a larger share here than anywhere else.

Germany Wearable Cardiac Monitoring Devices Market Snapshot

MetricValue
Market Size (2025)USD 171.3 Mn
Forecast Value (2035)USD 518.0 Mn
CAGR (2026–2035)11.7%
Germany wearable cardiac monitoring devices market — USD 171.3 Mn in 2025, 11.7% CAGR | Vectomat Insights
The Germany market grows from USD 171.3 Mn in 2025 to about USD 518.0 Mn by 2035 at a 11.7% CAGR. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

Asia Pacific Wearable Cardiac Monitoring Devices Market

Asia Pacific is where consumer electronics giants turn cardiac features into medical claims. The region holds 24.0% of 2025 revenue (USD 525.0 Mn) and is the fastest-growing region. South Korea is worth USD 105.0 Mn and compounds at 15.5% a year to about USD 443.6 Mn by 2035, after MFDS cleared Samsung's Galaxy Watch screen for left ventricular systolic dysfunction in October 2025. Japan, at USD 147.0 Mn and 13.6% a year, and China, where Huawei registers watches as medical devices, add scale. India's digital health ID system passed 900 million accounts in 2026. Fragmented registration rules are the main hurdle. Samsung's heart-failure feature, launched in Korea first, is the template for the region.

South Korea Wearable Cardiac Monitoring Devices Market Snapshot

MetricValue
Market Size (2025)USD 105.0 Mn
Forecast Value (2035)USD 443.6 Mn
CAGR (2026–2035)15.5%
South Korea wearable cardiac monitoring devices market — USD 105.0 Mn in 2025, 15.5% CAGR | Vectomat Insights
The South Korea market grows from USD 105.0 Mn in 2025 to about USD 443.6 Mn by 2035 at a 15.5% CAGR. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

Latin America Wearable Cardiac Monitoring Devices Market

Brazil sets the region's pace, and ANVISA's earlier approval of Samsung Health Monitor's ECG and blood pressure apps opened the consumer channel. Latin America holds 5.0% of 2025 revenue (USD 109.4 Mn). Prescription patch services are still concentrated in private hospital networks in São Paulo and Rio de Janeiro, and public-system Holter capacity lags demand. The constraint is coverage: most ambulatory ECG and wearable spending is paid out of pocket or by private plans. Latin America's USD 109.4 Mn base in 2025 is smaller than Germany's market alone.

The Middle East Wearable Cardiac Monitoring Devices Market

Gulf hospitals are buying remote cardiac programmes as part of national digital health plans. The Middle East holds 4.0% of 2025 revenue (USD 87.5 Mn), led by Saudi Arabia and the UAE. Garmin extended its ECG App to customers in both countries, and Cleveland Clinic Abu Dhabi runs a remote heart monitoring programme for patients at home. The main limit is clinical review capacity rather than device supply. King Abdullah Medical City in Makkah launched smart heart-failure monitoring technology in July 2026.

Africa Wearable Cardiac Monitoring Devices Market

Africa's wearable cardiac demand sits mostly in private hospital groups. The region holds 3.0% of 2025 revenue (USD 65.6 Mn), with South Africa and Egypt the leading markets. In November 2025 Netcare agreed with Corsano Health to roll out continuous wearable monitoring across general wards in South Africa, a hospital-led model rather than a consumer one. Weak reimbursement and uneven connectivity outside major cities hold adoption back. For now, the African market is defined by inpatient wearables bought by private operators, not by prescription patches sent home.

Wearable cardiac monitoring devices market share by region — North America leads with 37.0% | Vectomat Insights
North America holds 37.0% of 2025 revenue, ahead of Europe at 27.0% and Asia Pacific at 24.0%, the fastest-growing region. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.
Wearable cardiac monitoring devices product type mix by region — patches lead in North America | Vectomat Insights
ECG/heart rate patches lead the product mix in all three largest regions, with Holter monitors strongest in Europe and smartwatches strongest in Asia Pacific. Source: Vectomat Insights, Wearable Cardiac Monitoring Devices Market Report.

Full Country Coverage

RegionCountries Covered
North AmericaThe U.S., Canada, Mexico
EuropeGermany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe
Asia PacificChina, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific
Latin AmericaBrazil, Argentina, Colombia, Chile, Peru, Rest of Latin America
The Middle EastGCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East
AfricaSouth Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa

Note: Country-level market sizing, historical data, and forecasts available for all geographies listed. Custom regional add-ons available — contact sales@vectomatinsights.com

How Governments Are Supporting the Wearable Cardiac Monitoring Devices Market

Remote monitoring reimbursement — The U.S. CMS CY2026 Physician Fee Schedule, finalised on 31 October 2025, created remote physiologic monitoring codes for 2 to 15 days of data and a shorter 10-minute management code, opening payment for brief home cardiac studies. (CMS CY2026 Medicare Physician Fee Schedule (remote physiologic monitoring codes))

Hospital-at-home capacity — NHS England delivered more than 10,000 virtual ward beds and extended them to heart failure patients, creating public demand for wearable monitoring after discharge. (NHS England Virtual Wards Programme)

Cross-border health data rules — The European Health Data Space Regulation (EU) 2025/327 entered into force in March 2025, phasing in common rules for patient access to and sharing of electronic health data, including data from wellness and wearable apps. (European Health Data Space Regulation (EU) 2025/327)

National digital health identity — India's Ayushman Bharat Digital Mission passed 900 million health ID accounts in 2026, giving device makers a national rail for linking home ECG results to patient records. (Ayushman Bharat Digital Mission (ABDM))

What's New in the Wearable Cardiac Monitoring Devices Market?

Recent activity mixes consolidation with a steady run of FDA clearances, and most of it pushes clinical-grade recording into the home or onto the ward.

DateCompanyTypeDescriptionMarket Impact
Aug 2026iRhythm TechnologiesM&AAgreed to acquire wearable biosensor company VitalConnect for about USD 287.5 Mn, adding the VitalPatch platform with up to 30 days of continuous monitoring across 11 physiological parameters. [source]Extends the patch leader from ambulatory ECG into inpatient and hospital-to-home monitoring, raising the bar for rivals on acuity coverage.
Aug 2026BittiumProduct LaunchLaunched the Faros Pro ambulatory ECG recorder with the EasyFlex single-use one-lead patch, CE marked under EU MDR for recordings from 24 hours to 30 days. [source]Refreshes a 600,000-unit Faros installed base and strengthens European long-term Holter supply outside the U.S.
Jan 2026AliveCorRegulatoryReceived FDA clearance for new KAI 12L determinations on the Kardia 12L ECG system, bringing the total to 39 cardiac determinations. [source]Moves portable ECG closer to full 12-lead interpretation at the point of care and in the home.
Dec 2025WearlinqInvestmentRaised a USD 14 Mn Series A led by AIX Ventures to scale its eWave continuous wireless multi-lead ECG wearable. [source]Signals investor appetite for clinical-grade multi-lead wearables that sit between single-lead patches and 12-lead systems.
Dec 2025HeartBeamRegulatoryReceived FDA 510(k) clearance for a cable-free synthesized 12-lead ECG system for at-home arrhythmia assessment, after a successful appeal. [source]Opens a home 12-lead category for physician-directed arrhythmia assessment.
Sep 2025AppleRegulatoryReceived FDA clearance for Hypertension Notifications on Apple Watch, launched with watchOS 26. [source]Adds a cardiovascular screening feature to one of the largest installed bases of ECG-capable watches.

Research Methodology

Overall approach

VMI sized the Wearable Cardiac Monitoring Devices market both bottom-up and top-down. The bottom-up model multiplies monitoring studies (patch, Holter and telemetry orders) and the cardiac share of ECG-capable smartwatch and chest-strap sales by average selling prices in each country. The top-down model starts from reported revenue of prescription monitoring companies such as iRhythm, Philips and Boston Scientific, plus the cleared-feature share of consumer wearable revenue, and allocates it by product type, application, end user and channel. The two were reconciled to a 2025 base of USD 2,187.4 Mn.

Primary research

Primary inputs came from interviews with cardiologists, electrophysiologists, heart failure nurse leads, hospital procurement managers, independent diagnostic testing facility operators and product managers at patch, Holter and smartwatch makers across North America, Europe and Asia Pacific. Interviews covered study volumes, wear times, prices per study, reimbursement exposure and the share of smartwatch alerts that lead to a prescription workup.

Secondary research

Secondary research drew on FDA 510(k) and De Novo databases, the FDA AI-enabled device list, EU MDR certificates, MFDS and NMPA approvals, CMS Physician Fee Schedule rules for long-term ECG and remote monitoring codes, company annual reports and earnings calls, smartwatch shipment data from IDC and Counterpoint, and epidemiology from WHO and the Global Burden of Disease study.

Data validation

Segment and regional values were reconciled to the 2025 base-year total for every dimension, country values were checked against their regional totals, and the patch and telemetry segments were cross-checked against reported revenue of the leading monitoring companies. Growth rates were tested against reimbursement changes, clearance timelines and smartwatch shipment trends before the forecast was finalised.

Read the full VMI market sizing & forecasting methodology →

Market Coverage Definitions

How this report defines the scope of the Wearable Cardiac Monitoring Devices Market: what each segment and sub-segment includes.

SegmentMarket Coverage Definition
By Product TypeSegments the market by the form factor of the monitoring device, covering ECG and heart rate patches, smartwatches with ECG, wearable Holter monitors, and chest straps and other form factors.
By ApplicationSegments the market by the clinical or consumer purpose the device serves, covering arrhythmia detection, heart failure management, post-surgical monitoring, and fitness and wellness monitoring.
By End UserSegments the market by who uses the device, covering homecare and direct-to-consumer users, hospitals and clinics, and ambulatory cardiac centers.
By Distribution ChannelSegments the market by how the device reaches the end user, covering direct-to-consumer and retail, hospital procurement, and online channels.

By Product Type

Sub-SegmentMarket Coverage Definition
ECG/Heart Rate PatchesAdhesive, skin-worn patches that continuously record ECG or heart rate data over extended periods, the largest product category given their widespread use in both prescribed arrhythmia monitoring and consumer fitness tracking.
Smartwatches with ECGConsumer smartwatches with an integrated single-lead ECG sensor, allowing users to record an on-demand ECG reading for heart rhythm screening alongside general fitness tracking features.
Wearable Holter MonitorsPortable, wearable devices that continuously record a full ECG over 24 hours to several weeks, used primarily in clinical settings to capture intermittent arrhythmias that a single ECG reading would miss.
Chest Straps & OthersChest-worn heart rate monitoring straps and other wearable form factors, typically used for fitness and wellness monitoring rather than clinical arrhythmia detection.

By Application

Sub-SegmentMarket Coverage Definition
Arrhythmia DetectionMonitoring aimed at detecting irregular heart rhythms such as atrial fibrillation, the largest application given the clinical importance of capturing intermittent arrhythmia events that occur outside a standard in-office ECG reading.
Heart Failure ManagementOngoing monitoring of patients with diagnosed heart failure to track physiological trends and flag early signs of decompensation before a hospital admission becomes necessary.
Post-Surgical MonitoringShort-term wearable monitoring following cardiac or other surgical procedures to detect early complications during the recovery period.
Fitness & Wellness MonitoringHeart rate and rhythm tracking for general fitness and wellness purposes rather than diagnosis or treatment of a specific cardiac condition.

By End User

Sub-SegmentMarket Coverage Definition
Homecare/Direct-to-ConsumerIndividual consumers using wearable cardiac monitoring devices at home, either through a physician-prescribed monitoring program or as a self-purchased consumer health device, the largest end-user group given the shift of cardiac monitoring out of clinical settings.
Hospitals & ClinicsHospitals and outpatient clinics using wearable cardiac monitoring devices as part of inpatient care or prescribed outpatient monitoring programs.
Ambulatory Cardiac CentersSpecialty outpatient cardiac centers prescribing and managing wearable cardiac monitoring programs for patients referred for arrhythmia evaluation or ongoing cardiac disease management.

By Distribution Channel

Sub-SegmentMarket Coverage Definition
Direct-to-Consumer/RetailWearable cardiac monitoring devices sold directly to consumers through retail channels, the largest distribution channel given the growth of consumer smartwatches and self-purchased monitoring patches.
Hospital ProcurementDevices purchased by hospitals and health systems for use in prescribed monitoring programs, typically procured through group purchasing organizations or direct manufacturer contracts.
Online ChannelsDevices sold through manufacturer websites and e-commerce platforms, a growing channel for both consumer smartwatches and direct-to-consumer monitoring patches.

Market Assessment Framework

The four-step framework used to size and validate the Wearable Cardiac Monitoring Devices market.

  1. 1

    Bottom-Up Approach

    Market value is built up from individually identified wearable cardiac monitoring products across ECG and heart rate patches, ECG-enabled smartwatches, wearable Holter monitors, and chest straps, starting with unit shipment volumes and average selling prices by product type. Revenue for each category is aggregated upward to the product type, application, and total market level.

  2. 2

    Volume-Based Assessment

    Device usage volume is estimated separately for homecare and direct-to-consumer users, hospitals and clinics, and ambulatory cardiac centers, since these end users adopt wearable cardiac monitoring at different rates and for different monitoring durations. Prescribed monitoring episodes, consumer device penetration, and reimbursement coverage are modeled by end user and region rather than applying a single usage assumption across the market.

  3. 3

    Price & Revenue Benchmarking

    Per-unit and per-episode pricing for patches, smartwatches, and Holter monitors is benchmarked against publicly disclosed retail prices, payer reimbursement rates, and distributor pricing, adjusted for regional differences. Benchmarking distinguishes between one-time consumer device purchases and prescribed monitoring services billed per episode, which follow different revenue patterns.

  4. 4

    Market Validation & Triangulation

    Estimates built from the bottom-up and volume-based approaches are cross-checked against company-reported device shipments and revenue, regulatory clearance decisions, and publicly announced acquisition, funding, and recall activity affecting wearable cardiac monitoring device supply. Discrepancies beyond an acceptable range are investigated and reconciled before the estimate is finalized.

Specialized Analyst Insights

Analyst view · VMI Medical Devices & Equipment research team

The Philips BTPS-1000 recall is a reminder that software, not the wearable sensor itself, is increasingly where clinical risk concentrates in cardiac monitoring devices. The underlying hardware was not the problem; a software configuration issue caused clinically significant ECG events to go unflagged for nearly two years before detection. As wearable cardiac monitoring shifts more analysis to onboard or cloud-based software and AI-assisted arrhythmia detection, software validation and post-market surveillance become as important to device safety as the physical sensor design.

The resolution of the Apple-AliveCor litigation removes a years-long cloud of uncertainty over Apple Watch ECG functionality, but it also illustrates how patent risk in consumer cardiac wearables often resolves in favor of the larger platform holder. AliveCor's underlying patents were invalidated before the final antitrust claim was rejected, a pattern smaller device makers competing against platform companies with built-in ECG features should weigh carefully when evaluating intellectual property strategy in this space.

Consolidation in wearable cardiac monitoring is increasingly about combining monitoring duration and acuity range rather than simply adding scale. iRhythm's acquisition of VitalConnect pairs iRhythm's long-term ambulatory ECG monitoring with VitalConnect's broader multi-parameter biosensor platform spanning inpatient, outpatient, and hospital-to-home settings, extending iRhythm's reach across a wider range of patient acuity rather than simply adding more of the same long-term ECG monitoring capacity it already has.

Early-stage funding continues to flow toward wearable ECG devices that emphasize clinical-grade multi-lead data over single-lead consumer screening. Wearlinq's funding round for its continuous, wireless 6-lead ECG wearable, and HeartBeam's FDA clearance for a cable-free synthesized 12-lead ECG system, both target a tier of diagnostic detail closer to a clinical Holter monitor than a consumer smartwatch, suggesting investors see room for wearables that compete on clinical data quality rather than consumer convenience alone.

Regional Regulations

Regulatory authorities and requirements across 9 jurisdictions
RegionKey Regulatory Authorities / FrameworksGovernment Regulations and Regulatory Considerations
North AmericaU.S.U.S. FDAWearable cardiac monitoring devices are regulated by the FDA, generally cleared through the 510(k) pathway as Class II devices, with ECG algorithms and AI-based arrhythmia detection features reviewed as part of the same submission. Devices sold purely for fitness and wellness purposes without a diagnostic claim generally fall outside FDA device regulation.
EuropeEuropean Commission, Notified BodiesWearable cardiac monitoring devices with a diagnostic or monitoring function fall under the EU Medical Device Regulation, requiring CE marking through a notified body, while consumer wellness-only devices without a medical claim generally fall outside MDR scope.
Asia PacificJapanMHLW, PMDAWearable cardiac monitoring devices with a diagnostic function are regulated under Japan's Pharmaceuticals and Medical Devices Act, with PMDA reviewing ECG algorithm performance data as part of device approval.
Asia PacificChinaNMPAChina's NMPA regulates wearable cardiac monitoring devices as medical devices when marketed for diagnostic use, with registration requirements that vary by risk classification and growing domestic manufacturing of ECG-enabled wearables.
Asia PacificIndiaCDSCOWearable cardiac monitoring devices with a diagnostic claim fall under India's Medical Device Rules administered by the CDSCO, while consumer fitness-focused devices without a medical claim generally fall outside device registration requirements.
Asia PacificSouth KoreaMFDSSouth Korea's Ministry of Food and Drug Safety regulates wearable cardiac monitoring devices as medical devices when marketed with a diagnostic function, with a dedicated digital health device review track supporting faster evaluation of connected monitoring devices.
Latin AmericaBrazilANVISAWearable cardiac monitoring devices with a diagnostic function are regulated as medical devices by ANVISA, with consumer wellness devices generally outside medical device registration requirements.
Middle EastNational health product regulatory authorities, GCC frameworksWearable cardiac monitoring device regulation continues to develop across the region alongside growing adoption of remote patient monitoring programs by national health systems.
Global / InternationalISO, IECISO and IEC standards support electrical safety, electromagnetic compatibility, and ECG signal quality requirements for wearable cardiac monitoring devices worldwide, supporting a consistent baseline for device performance and safety evaluation across markets.

Strategic Activities

5 strategic developments shaping the Wearable Cardiac Monitoring Devices Market
DateCompany / CompaniesDevelopment TypeDevelopment and Impact on Market
Jan 2025Philips, Braemar ManufacturingRecallThe FDA classified a recall of Philips' Mobile Cardiac Telemetry Monitoring service and its BTPS-1000 wearable sensor patch as Class I, the most serious category, after a software configuration issue caused some ECG recordings between July 2022 and July 2024 to go unflagged for clinician review. The FDA received reports of 109 injuries and two deaths linked to the issue. [source]
Dec 2025HeartBeamRegulatory ClearanceHeartBeam received FDA 510(k) clearance for a cable-free, synthesized 12-lead ECG system for at-home arrhythmia assessment, with results reviewed by an on-demand board-certified cardiologist. The company planned a limited early-2026 launch with select concierge and preventive cardiology groups to validate real-world performance before a broader rollout. [source]
Jan 2026Apple, AliveCorLegal ResolutionThe U.S. Court of Appeals for the Ninth Circuit affirmed summary judgment in Apple's favor, rejecting AliveCor's claim that Apple illegally monopolized the market for heart rhythm analysis apps on Apple Watch. The ruling followed a March 2025 appeals court decision that had already confirmed the invalidation of three AliveCor patents underlying the dispute, closing out years of patent and antitrust litigation over Apple Watch ECG functionality. [source]
Jan 2026WearlinqFundingWearlinq, maker of the eWave continuous wireless 6-lead ECG wearable, raised a $14 million Series A led by AIX Ventures plus $5 million in venture debt, with continued participation from existing backers including SpringTide Ventures, Berkeley Catalyst Fund, and Amino Capital. The company said the funding would support scaling eWave nationally to reach a larger patient population. [source]
Aug 2026iRhythm Holdings, VitalConnectAcquisitioniRhythm Holdings agreed to acquire wearable biosensor company VitalConnect for approximately $287.5 million, combining VitalConnect's FDA-cleared 4-in-1 biosensor platform, capable of up to 30 days of continuous monitoring across 11 physiological parameters, with iRhythm's existing Zio long-term ECG monitoring platform. The deal was framed as expanding iRhythm's reach across a wider range of patient acuity levels. [source]

Related Analysis

Blog · Medical Devices & Equipment

In Wearable Cardiac Monitoring, the Sensor Isn't the Risk Anymore. The Software Is.

A software bug, not a faulty sensor, triggered the most serious recall in wearable cardiac monitoring in years. Meanwhile, a long-running patent fight ended quietly in Apple's favor, and fresh money kept flowing toward wearables built for clinical detail rather than consumer convenience.

Read the article →

Table of Contents: Wearable Cardiac Monitoring Devices Market Report

13 chapters · 98 tables & 72 figures. Expand a chapter to see its sub-sections.

Introduction
  1. Report Description and Scope
  2. Research Assumptions and Currency
Research Methodology
  1. Primary Research
  2. Secondary Research
  3. Market Size Estimation and Triangulation
Executive Summary
  1. Key Findings
  2. Analyst Recommendations
Wearable Cardiac Monitoring Devices Market: Dynamics
  1. Growth Drivers
  2. Restraints
  3. Opportunities
  4. Challenges
  5. AI Influence on Arrhythmia Analysis
Reimbursement and Regulatory Analysis
  1. U.S. Long-Term ECG and Remote Monitoring Codes
  2. EU MDR and Notified Body Requirements
  3. Asia Pacific Device Registration Pathways
Wearable Cardiac Monitoring Devices Market, By Product Type
  1. Overview and Share Analysis, By Product Type
  2. ECG/Heart Rate Patches
  3. Smartwatches with ECG
  4. Wearable Holter Monitors
  5. Chest Straps & Others
  6. Production & Volume Analysis, By Product Type, 2025
Wearable Cardiac Monitoring Devices Market, By Application
  1. Overview and Share Analysis, By Application
  2. Arrhythmia Detection
  3. Heart Failure Management
  4. Post-Surgical Monitoring
  5. Fitness & Wellness Monitoring
Wearable Cardiac Monitoring Devices Market, By End User
  1. Overview and Share Analysis, By End User
  2. Homecare/Direct-to-Consumer
  3. Hospitals & Clinics
  4. Ambulatory Cardiac Centers
Wearable Cardiac Monitoring Devices Market, By Distribution Channel
  1. Overview and Share Analysis, By Distribution Channel
  2. Direct-to-Consumer/Retail
  3. Hospital Procurement
  4. Online Channels
Wearable Cardiac Monitoring Devices Market, By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. The Middle East
  6. Africa
Competitive Landscape
  1. Market Share and Positioning Analysis
  2. Strategic Developments: M&A, Clearances and Funding
  3. Value Chain Analysis
Company Profiles
  1. iRhythm Technologies
  2. Apple
  3. Samsung Electronics
  4. Philips
  5. Boston Scientific
  6. Garmin
  7. AliveCor
  8. Google (Fitbit)
  9. Withings
  10. Bittium
  11. Omron Healthcare
  12. Huawei
  13. VitalConnect
  14. HeartBeam
  15. Biotricity
Appendix
  1. Abbreviations
  2. Related Reports

List of Tables (selected)

  1. Wearable Cardiac Monitoring Devices Market Size, 2023–2035 (USD Million)
  2. Wearable Cardiac Monitoring Devices Market Size, By Product Type, 2023–2025 (USD Million)
  3. Wearable Cardiac Monitoring Devices Market Size, By Application, 2023–2025 (USD Million)
  4. Wearable Cardiac Monitoring Devices Market Size, By End User, 2023–2025 (USD Million)
  5. Wearable Cardiac Monitoring Devices Market Size, By Distribution Channel, 2023–2025 (USD Million)
  6. Wearable Cardiac Monitoring Devices Market Production & Volume, By Product Type, 2025 (units shipped)
  7. Wearable Cardiac Monitoring Devices Market Share, By Region, 2025 (%)
  8. North America Wearable Cardiac Monitoring Devices Market Size, By Country, 2023–2035 (USD Million)
  9. Europe Wearable Cardiac Monitoring Devices Market Size, By Country, 2023–2035 (USD Million)
  10. Asia Pacific Wearable Cardiac Monitoring Devices Market Size, By Country, 2023–2035 (USD Million)
  11. Latin America Wearable Cardiac Monitoring Devices Market Size, By Country, 2023–2035 (USD Million)
  12. The Middle East Wearable Cardiac Monitoring Devices Market Size, By Country, 2023–2035 (USD Million)
  13. Africa Wearable Cardiac Monitoring Devices Market Size, By Country, 2023–2035 (USD Million)
  14. U.S. Wearable Cardiac Monitoring Devices Market Snapshot, 2023–2035
  15. Germany Wearable Cardiac Monitoring Devices Market Snapshot, 2023–2035
  16. South Korea Wearable Cardiac Monitoring Devices Market Snapshot, 2023–2035
  17. Wearable Cardiac Monitoring Devices Market: Key Companies, Focus and Strategy
  18. Wearable Cardiac Monitoring Devices Market: Recent Developments, 2025–2026
  19. Wearable Cardiac Monitoring Devices Market: Regulatory Pathways by Region

List of Figures (selected)

  1. Wearable Cardiac Monitoring Devices Market Size, 2025–2035 (USD Million)
  2. Wearable Cardiac Monitoring Devices Market: Drivers, Restraints, Opportunities & Challenges
  3. Wearable Cardiac Monitoring Devices Market Share by Region, 2025
  4. Wearable Cardiac Monitoring Devices Market: Segmentation Overview
  5. Wearable Cardiac Monitoring Devices Market Share, By Product Type, 2025 (%)
  6. Wearable Cardiac Monitoring Devices Market Share, By End User, 2025 (%)
  7. Wearable Cardiac Monitoring Devices Market: Product Type Mix by Region
  8. Wearable Cardiac Monitoring Devices Market: Competitive Landscape
  9. Wearable Cardiac Monitoring Devices Market: At a Glance
  10. U.S. Wearable Cardiac Monitoring Devices Market Size, 2023–2035
  11. Germany Wearable Cardiac Monitoring Devices Market Size, 2023–2035
  12. South Korea Wearable Cardiac Monitoring Devices Market Size, 2023–2035

You May Also Be Interested In

Planned

Remote Patient Monitoring Market

Shares the reimbursement codes, home-care buyers and hospital-at-home programmes that drive wearable cardiac demand.

Planned

Smartwatch Market

Sets the installed base and upgrade cycles behind the smartwatches with ECG segment.

Planned

Insertable Cardiac Monitors Market

Competes with long-term patches for cryptogenic stroke and unexplained syncope monitoring.

Planned

Atrial Fibrillation Ablation Devices Market

Sits downstream of AF detection, so diagnosis volumes from wearables feed ablation demand.

All VMI market research reports available in PDF. Contact sales@vectomatinsights.com

Frequently Asked Questions

What does the VMI Wearable Cardiac Monitoring Devices report include?

The report includes market sizing for 2023–2025 and forecasts to 2035 across four segmentation dimensions: product type, application, end user and distribution channel. It covers six regions and 35+ countries, a production and volume analysis in units shipped, a drivers-restraints-opportunities-challenges review, an AI impact section, a value chain analysis and profiles of 15 companies, presented in 300+ pages with 98 tables and 72 figures, according to Vectomat Insights.

What is the Wearable Cardiac Monitoring Devices market size and forecast?

The market was valued at USD 2,187.4 Mn in 2025 and is forecast to reach USD 7,597.9 Mn by 2035, a 13.26% CAGR. Homecare/direct-to-consumer is the fastest-growing end user at 16.76% a year, and online channels are the fastest distribution route at 19.77%. By application, fitness and wellness monitoring grows fastest at 19.69%, while heart failure management is the fastest clinical use at 15.71%, according to Vectomat Insights.

How is the Wearable Cardiac Monitoring Devices market segmented in this report?

The market is segmented by product type (ECG/heart rate patches, smartwatches with ECG, wearable Holter monitors, chest straps and others), application (arrhythmia detection, heart failure management, post-surgical monitoring, fitness and wellness monitoring), end user (homecare/direct-to-consumer, hospitals and clinics, ambulatory cardiac centers) and distribution channel (direct-to-consumer/retail, hospital procurement, online channels). Each dimension has revenue tables for 2023–2025 and share charts for the base year, according to Vectomat Insights.

Which countries are covered in this report?

The report covers 35+ countries across six regions: North America, Europe, Asia Pacific, Latin America, Africa and the Middle East, each analysed on its own. Featured countries include the U.S., Canada, Germany, the U.K., South Korea, Japan, China, Brazil, Saudi Arabia, the UAE, South Africa and Egypt, and detailed snapshots are provided for the U.S., Germany and South Korea, according to Vectomat Insights.

What customization options are available?

Every buyer gets up to 10% free customization at no extra cost. Typical requests include extra country splits, additional company profiles, and deeper sub-segment cuts such as patch wear duration, single-lead versus multi-lead ECG, or prescription versus consumer device revenue. Larger custom scopes, such as a payer-mix model for U.S. long-term ECG codes, can be quoted separately through sales@vectomatinsights.com, according to Vectomat Insights.

How can I access or purchase the Wearable Cardiac Monitoring Devices report?

You can request a free sample, buy the full report or send an inquiry from the report page on the Vectomat Insights website. The report is delivered as a PDF by email and through the online download portal. For enterprise licences, multi-user access or bundled reports with adjacent cardiology and remote monitoring markets, contact sales@vectomatinsights.com for pricing and licence terms, according to Vectomat Insights.

What research methodology does VMI use for this report?

VMI combines primary interviews with cardiologists, electrophysiologists, procurement managers and device makers with secondary research from FDA, EU MDR, MFDS and CMS records, company filings and shipment data. The market is sized bottom-up from monitoring studies and device sales and top-down from company revenue, then segment, regional and country values are reconciled to the 2025 base year and cross-checked against reported revenue, according to Vectomat Insights.

Access the Complete Wearable Cardiac Monitoring Devices Market Report

300+ pages | 98 tables & 72 figures | 2026–2035 | All 6 regions | PDF

Contact: sales@vectomatinsights.com

About Vectomat Insights

Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.

Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com

Request a free sample

Ready to go deeper? Request a free sample of the VMI Wearable Cardiac Monitoring Devices Report — preview key data tables, segmentation depth, and regional forecasts before purchasing.

Your request goes straight to our sales team. We reply within one business day. Details are used only to answer this request (see our privacy policy).

About this report

Analyst team
Sneha Reddy
Sneha Reddy
Author · Senior Research Analyst

Sneha Reddy is a Senior Research Analyst at Vectomat Insights with more than 13 years of experience in market research and industry analysis, focused on healthcare and pharmaceutical intelligence.

Sunil Bhosale
Sunil Bhosale
Reviewer · Senior Research Manager

Sunil Bhosale is a Senior Research Manager at Vectomat Insights and a market research and intelligence professional with expertise in market sizing, forecasting, competitive intelligence and strategic analysis across pharmaceutical and healthcare markets.

Meet the research team →
Cite this reportVectomat Insights. (2026). Wearable Cardiac Monitoring Devices Market Report, 2026–2035. Retrieved from https://www.vectomatinsights.com/report/wearable-cardiac-monitoring-devices-market